Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study

臺大醫院;臺大醫院-內科部;臺大醫院-外科部;臺大醫學院-內科;臺大醫學院-外科;Chen, Li-TzongLi-TzongChenJeng, Long-BinLong-BinJengHsiao, Chin-FuChin-FuHsiaoWu, Cheng-ChungCheng-ChungWuLee, Wei-ChenWei-ChenLeeWang, Tsang-EnTsang-EnWangLee, Po-HuangPo-HuangLeeChen, Chao-LongChao-LongChenChen, I-SuI-SuChenLee, King-TehKing-TehLeeHsieh, Chung-BaoChung-BaoHsiehHwang, Wei-ShouWei-ShouHwangYang, Mei-DueMei-DueYangYang, Yang-SenYang-SenYangLin, Deng-YnDeng-YnLinChen, Miin-FuMiin-FuChenChen, Pei-JerPei-JerChen2017-12-212018-07-112017-12-212018-07-112015http://ntur.lib.ntu.edu.tw//handle/246246/284000Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study